USCWA
SRPT icon

U.S. Capital Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36
Closed -$4.67K – 1413
2022
Q4 		$4.67K Buy
+36
New +$4.17K ﹤0.01% 1398

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

U.S. Capital Wealth Advisors's SRPT Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 36 shares — an estimated $4.67K sold.

U.S. Capital Wealth Advisors first reported a position in SRPT in Q4 2022 and held it in 1 quarter. The position peaked at $4.67K in Q4 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 36 Sarepta Therapeutics shares in Q1 2023, an estimated $4.67K.
  • U.S. Capital Wealth Advisors first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Sarepta Therapeutics position peaked at $4.67K in Q4 2022.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.